Masimo (NASDAQ:MASI) had its price objective raised by research analysts at Piper Sandler from $280.00 to $310.00 in a report issued on Thursday, The Fly reports. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s price objective suggests a potential upside of 12.21% from the company’s current price.
A number of other equities research analysts also recently issued reports on MASI. Zacks Investment Research downgraded shares of Masimo from a “buy” rating to a “hold” rating and set a $258.00 target price for the company. in a research report on Thursday, October 8th. BidaskClub upgraded shares of Masimo from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Tuesday, October 6th. Stifel Nicolaus boosted their price objective on Masimo from $255.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Finally, Raymond James boosted their price target on shares of Masimo from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, October 28th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Masimo currently has a consensus rating of “Buy” and a consensus target price of $260.71.
Masimo stock opened at $276.27 on Thursday. Masimo has a 1 year low of $143.90 and a 1 year high of $284.86. The firm’s 50 day moving average price is $266.33 and its two-hundred day moving average price is $238.93. The firm has a market cap of $15.21 billion, a price-to-earnings ratio of 71.76, a price-to-earnings-growth ratio of 3.90 and a beta of 0.87.
In related news, EVP Anand Sampath sold 30,000 shares of the business’s stock in a transaction on Tuesday, December 15th. The stock was sold at an average price of $265.59, for a total value of $7,967,700.00. Following the completion of the sale, the executive vice president now directly owns 28,782 shares in the company, valued at approximately $7,644,211.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Micah W. Young sold 10,000 shares of Masimo stock in a transaction on Monday, October 19th. The stock was sold at an average price of $239.00, for a total value of $2,390,000.00. Following the sale, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at approximately $2,390,000. The disclosure for this sale can be found here. Over the last quarter, insiders sold 191,781 shares of company stock worth $50,364,663. Corporate insiders own 11.50% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Captrust Financial Advisors acquired a new stake in Masimo during the second quarter worth approximately $25,000. Steward Partners Investment Advisory LLC lifted its position in shares of Masimo by 222.2% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 116 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 80 shares during the period. NEXT Financial Group Inc acquired a new stake in shares of Masimo during the 3rd quarter worth $40,000. First Horizon Advisors Inc. lifted its position in Masimo by 47.2% during the third quarter. First Horizon Advisors Inc. now owns 293 shares of the medical equipment provider’s stock worth $69,000 after purchasing an additional 94 shares during the period. Finally, Banque Cantonale Vaudoise acquired a new position in shares of Masimo in the 3rd quarter valued at approximately $71,000. Institutional investors own 78.75% of the company’s stock.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Further Reading: Initial Public Offering (IPO)
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.